Hypothesis: the central issue with tapering is to find the best way to assess what the minimal effective dose is in a patient. As this is done open label, it can be biased by nocebo and attribution effects. Disease activity guided tapering indeed underperforms, so many patients don't taper optimally. For example, in blinded studies half dosed etanercept is equal to full dose, but in DRESS 40% of patient could not dose reduce at all. I think that using a more patient centered approach might aggravate this problem. So how do you think to counter this increase nocebo and attribution effects? In fact, reading your intervention and flare criteria, I don't think you really use a more patient centered approach than usual DAS28 /ASDAS bases treat to target, with usual SDM. When the research question (which is not entirely spelled out) is whether patient centered tapering is better than protocol guided, then a DRESS/STRASS like comparator group is preferably above usual care.
Primary outcome: this is I think somewhat ambiguously stated in the abstract. You state that you are comparing % of patients successfully tapered (< 50% of DDD) and being in remission, however, it seems you use a continuous outcome of disease activity. The power for superiority in % <50% DDD is obviously very high, because this is an open door. In patients who are being tapered more will use a lower dose than patients who are not tapered. You do not fully explain the 0.5 NI margin, but I think its fine. Being in remission is a suboptimal performing flare criterion, e.g. it is much to specific. When you include patients in deep remission, regression to the mean will result in many patient not being in deep remission anymore. See van der Maas 2013 OMERACT flare criteria paper. You analayse the mean in DAS28/ASDAS change, so this might not be an issue, but when talking about patients in remission it is.
Patients: for RA patients this work has been done in the last year, see recent systematic reviews on the subject. Doing this for PsA and axSpA is important, because evidence is limited there. Consider focusing on those diseases Remission as inclusion, especially this deep remission is troublesome. Firstly, those patients are rare, many patients are in LDA or normal remission, and treatment is not intensified. So a tapering study should included preferably all patient who have reached their treatment goal, and more often than not, it is not deep remission. Also, patients themselves identify the patient acceptable symptom state as being around DAS28 of between 3.0 and 3.5. Finally, a somewhat higher disease activity @ baseline is not a predictor (Effectmodifier) for successful tapering (tweehuijsen et al A &R 2017) . So, there is no scientific or clinical reason not to include LDA patients, and it limits generalisability. Introduction: -please include a review on bDMARD dose reduction, for example the Cochrane, Verhoef et al 2017, or the ARD Fautrel paper 2017. You fr example do not mention the STRASS Fautrel study -did you check trial registers on recruiting PsA ax SpA bDMARD tapering studies? There are I think two of them, one being DRESS PS in our center (Dutch trial register NTR). -line 58: This is a misconception I think. Many patient cannot stop directly, but this does not mean these patients could stop when they were slowly tapered. There are no data to suggest that, as successful stopping seems more rare even in tapering than in stopping trials. The benefit of tapering is to identify a third group, patient who can be tapered but not stopped. See also the Fautrel den Broeder paper 2015 best practices, -page 5 line 5: see my earlier comments. Patient guided tapering might motivate people better, but for sure it will lead to more expectation bias, nocebo and attribution. Please discuss these potential drawbacks. Of note, also in DRESS and STRASS tapering to the next step was Shared decision making between patients and physicians.
Methods: -you use a validated OMERACT Das28 flare criterion to assess flare and increase treatment, So, how is this different from the DRESS and STRASS studies? I don't see any more patient centeredness than in those studies -For PsA , DAS28 is a difficult to interpret measure. It misses out on skin, enthesis and axial complaints. Do you have any data on DAS28 based flare criteria in PsA? -Also, in PsA and axSpA -more so than in RA -extraarticular other associated disease might activate, like uveitis, psoriasis, IBD. Please add a strategy to cope with such an event.
Comparator strategy: in a pragmatic study, ofcourse also in the UC group tapering can happen. However, with a NI or equivalence study, the main analyses are done per protocol, because in contrast to superiority studies, this is the more conservative approach. Do you have a per protocol analyses plan, because you state ITT as primary analysis? CONSORT now I think has reporting guidelines extension for NI and equivalence studies, please check these. -You use three strata: in the analyses it is state of art to also correct for those strata, and preferably to show equivalence per stratum, at least drug and disease. Is this contemplated? -Multilevel analyses are fine, although you did not use a ML sample size calculation (I think for 2 levels they exist, not for n levels.) But the assumptions seem fine Minor comments: -The word novel (title) is overrated and used too often, suggest changing it to 'new' - Table 1 is very large, please include only main measurements
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GENERAL COMMENTS
Dear Authors, This novel protocol addresses an interesting subject on incorporating patient participation in bDMARD tapering trial for RA, PsA and AxSpa patients. Although the research questions are very clear, I have some remarks that in my opinion should be resolved/clarified since they may have effect on the interpretation of the results.
• The primary outcome is the difference in percentage of patients that have at least a 50% dose reduction after 18 months of follow-up while staying in remission.
The intervention is a combination of dose reduction and patient participation. It is not clear what % is expected to be due to patient education/participation and what due to the dose reduction. Since these are two interventions in one arm it should have been taken into account in the power calculation. Another way is to educate also the usual care patients.
•
The sample size was calculated based the expected results form previous studies in RA. In your study however, you include also PSA and axSPA, both indications that have shown to get flares after discontinuation bDMARDs. Therefor the expected % used in your power calculation is an overestimation that results in a smaller needed sample size than it should be. In my opinion this should be taken into account in the sample size calculation. Recalculated is advised.
• Another misinterpretation as you mentioned is using the DAS as flare outcome for PSA. However, especially these patients might stop dose reduction because of skin activity even when the joints are not inflamed. Please leave your comments for the authors below This study by Uhrenholt et al will compare biologic dose reduction strategy with disease activity and patient report of symptoms considered and usual care. This will be interesting, but it needs some clarification. R1, Q1: How will patient report of symptoms in the intervention group be considered by their physicians and what "usual care" in the control group will be like should be explained more in detail. Otherwise, the difference between the groups is unclear. R1, A1: Thank you for bringing to our attention that the process of patient reporting of symptoms of arthritis flare in the intervention group compared to the control group needed clarification. Action item: the following item is inserted under the section "Intervention (BIODOPT) group" on page 8 of the revised manuscript:
"The BIODOPT tapering algorithm is patient-centered with focus on the patient's own perception of arthritis activity during tapering; thereby, making the patient an equal partner in their disease management as expected and required by modern society. Compared to a strict tapering algorithm focusing only on e.g. DAS28crp or joint swelling, the patient-centered BIODOPT algorithm is expected to enhance patient motivation during tapering; thereby, possibly increasing compliance. If the patient has symptoms of flare due to tapering but the arthritis is in remission assessed by the physician, the patient is generally advised to continue tapering according to the BIODOPT algorithm but may remain at the current dose (or even go back one step in the algorithm) after agreement between the patient and the physician." Action item: the following item is inserted under the section "Comparator (Control) group" on page 9 of the revised manuscript:
"In contrast to the intervention group, the small portion of patients tapering bDMARDs in the control group will not follow a patient-centered algorithm." R1, Q2: Sample size calculation is a bit of concern. Should it be done in each disease separately? The authors referred to the results of the DRESS study in the calculation, but it was targeting rheumatoid arthritis. It is not clear that the results can be applied to PsA and AS. Is it all right that drop-out was not taken into consideration? R1, A2: Thank you for raising this concern as we have discussed the same aspect during the initial phase when designing the trial protocol. The sample size calculation for primary endpoint 1A was inspired from the RA-DRESS trial as it is one of the very few randomised, non-inferiority/equivalence trials exploring a disease activity guided tapering algorithm among patients with inflammatory arthritis. Based on the available literature (no randomised non-inferiority/equivalence study exploring a disease activity guided tapering algorithm is to our knowledge done in PsA or axSpA) it seems reasonable to assume that the percentage of patients with PsA or axSpA meeting primary endpoint 1A will be the same as for RA, which is now described in the revised introduction. In contrast to the DRESS study, the BIODOPT trial has two primary endpoints (1A and 1B) and both endpoints must be met i.e. proving a statistically significant reduction in biologics while maintaining an equivalent disease state. Drop-out considerations is now described in the paper.
Action item: the following item is inserted under the section "Introduction" on page 4 of the revised manuscript:
"However, a non-inferiority trial including AS in remission on adalimumab, etanercept, infliximab or golimumab, which was stopped prematurely due to funding problems, found that prolonging the dosing interval of anti-TNF by 25% was non-inferior to full dosage anti-TNF as LDA was maintained in 81.3% of patients in the tapered group and 83.8% of patient in the full dose group. (22) In addition, Cantini et al. showed in a RCT study that 90.4% of patients with AS on full dose etanercept and 86.3% of patients with AS on half dose etanercept was still in remission after a mean follow up of 21-22 months. (32) Furthermore, prospective observational studies in AS and axSpA have proven that a large proportion of patient maintain remission/LDA after tapering of bDMARDs. (33,34) In PsA, a prospective observation study has shown that 72% of patients treated with 25 mg etanercept maintained remission 1 year after a progressive dosage reduction with 21% receiving weekly dosage and 51% receiving a dosage every-other-week. (27) Additionally, in a case-control study including patients with PsA and RA in remission on adalimumab, the proportion of patients maintaining remission was statistically significant higher among patients with PsA (88.6%) than RA (17.6%) after 50% dosage reduction. (28)" Action item: the following item is inserted under the section "Sample size and power considerations" on page 11-12 of the revised manuscript: "This assumption is inspired from the DRESS-RA trial, which it is one of the very few randomised, non-inferiority/equivalence trials exploring a disease activity guided tapering algorithm among patients with inflammatory arthritis. (30) No randomised, non-inferiority/equivalence study exploring a disease activity guided tapering algorithm is to our knowledge done in PsA or axSpA, but based on the available literature it seems reasonable to assume that the percentage of patients with PsA or axSpA meeting primary endpoint 1A will be the same as for RA (22, 27, 28, 32) . Thus, the sample size calculation was not done for each disease separately." "Drop-out considerations is based on primary endpoint 1B, as this is the endpoint with the lowest power (0.868). In a two one-sided test analysis for additive equivalence of two-sample normal means with bounds -0.5 and 0.5 for the mean difference and a significance level of 0.05, assuming a mean difference of 0 and a common standard deviation of 1, a total sample size of 156 assuming an allocation ratio of 2 to 1 is required to obtain a power of at least 0.8 (power = 0.802). Thus, 24 dropouts (180-156) are allowed corresponding to 13%." R1, Q3: The remission criteria for PsA is based on DAPSA, but the monitoring and flare definition is based on DAS28-CRP. It is inconsistent. R1, A3: Thank you for this comment. DAPSA was chosen as inclusion (remission) criteria for PsA as it is a stringent index that contains 66/68 joint count and is one of the suggested efficacy scores by EULAR. With the stringent DAPSA remission criteria we believe that only patients in true remission is included which may not be the case if the DAS28crp was used as that index only contain 28 joint count. The (RA validated) DAS28 flare criteria was chosen for PsA as there currently are no flare criteria for PsA; however, we acknowledge that it would be desirably to monitor the patients with PsA using a PsA validated criteria e.g. DAPSA if this was possible.
Action item: the following item is inserted under the section "Discussion" on page 16 of the revised manuscript:
"However, we acknowledge that it would be desirably to monitor patients with PsA using a PsA validated flare criteria e.g. a DAPSA based flare criteria as DAPSA is used as remission criteria for enrolment in this trial. Nevertheless, DAPSA will be calculated for patients with PsA for each trial visit for further sub analysis." R1, Q4: Introduction section should be more refined. There are many studies investigating the possibility of bDMARDs tapering. R1, A4: Thank you for making it clear that the introduction needed refinement. The introduction is now revised for clarity including description of several tapering trials. Thus, the STRASS study is now included in the introduction as suggested by reviewer 2 together with two additional reviews on tapering of bDMARD in the reference list.
Action item: the following references is inserted in the section "Introduction" of the revised manuscript: In fact, reading your intervention and flare criteria, I don't think you really use a more patient centered approach than usual DAS28 /ASDAS bases treat to target, with usual SDM.
R2, A2: Thank you for this comment. In the initial phase of development of this trial, we examined different possibilities for blinding (e.g. sham spacing device); however, we did not find a feasible solution. Consequently, the trial became an open-label trial with no blinding of patients or research personnel to the intervention. We acknowledge, that open-label tapering studies incl. this trial can be biased by e.g. nocebo and/or attribution effects resulting in fewer patients being able to taper their bDMARD when compared with blinded studies as described by reviewer 2. However, compared to a strict tapering algorithm focusing only on e.g. DAS28crp or joint swelling (no patient involvement/shared decision making during tapering), the patient-centered BIODOPT tapering algorithm is expected to enhance patient motivation during tapering; thereby, possibly decreasing a nocebo effect. For clarity, the intervention incl. the patient-centered algorithm has now been described in greater detail in the section "Intervention (BIODOPT) group".
Action item: the following item is inserted under the section "Intervention (BIODOPT) group" on page 8 of the revised manuscript:
"The BIODOPT tapering algorithm is patient-centered with focus on the patient's own perception of arthritis activity during tapering; thereby, making the patient an equal partner in their disease management as expected and required by modern society. Compared to a strict tapering algorithm focusing only on e.g. DAS28crp or joint swelling, the patient-centered BIODOPT algorithm is expected to enhance patient motivation during tapering; thereby, possibly increasing compliance. If the patient has symptoms of flare due to tapering but the arthritis is in remission assessed by the physician, the patient is generally advised to continue tapering according to the BIODOPT algorithm but may remain at the current dose (or even go back one step in the algorithm) after agreement between the patient and the physician."
Action item: the following item is inserted under the section "Discussion" on page 15 of the revised manuscript:
"The BIODOPT trial evaluates a patient-centered tapering algorithm as it seems plausible that taking the patient's own assessment of arthritis activity into consideration during tapering will result in increased motivation and better adherence to the algorithm; thereby, possibly resulting in a higher rate of successful dosage reduction compared to previous studies with a stringent tapering algorithm without patient-involvement. Furthermore, a patient-centered tapering algorithm might minimise the risk of major flare as previous research in RA has shown that patients with flare have a significant higher score of several PROMs compared to patients without flare. (70)" "However, a limitation is that the trial personnel and the patients are not blinded to the intervention groups; thus, this could potentially lead to bias e.g. nocebo, expectation and/or attribution bias which would affect interpretation of the trial results." R2, Q3: When the research question (which is not entirely spelled out) is whether patient centered tapering is better than protocol guided, then a DRESS/STRASS like comparator group is preferably above usual care.
R2, A3: Thank you for making it clear, that the research question needed to be clarified. The research question is whether a patient-centered tapering algorithm is better than usual care practise; thus, not if it is better than a protocol guided tapering algorithm with no patient-involvement, which is why a DRESS/STRASS like comparator group was not chosen as the control group.
Action item: the following item is inserted/revised under the section "Introduction" on page 4 of the revised manuscript:
"We hypothesise, that a patient-centered tapering algorithm for bDMARDs will reduce dosage of biologics while disease activity remains stable."
"Thus, the aim of this study is to evaluate whether a patient-centered tapering strategy for bDMARDs will enable a significant dosage reduction while maintaining disease activity assessed 18 months from baseline compared with usual care." R2, Q4: Primary outcome: this is I think somewhat ambiguously stated in the abstract. You state that you are comparing % of patients successfully tapered (< 50% of DDD) and being in remission, however, it seems you use a continuous outcome of disease activity.
R2, A4: Thank you for bringing to our attention that the primary objective needed to be written more precisely in the abstract and this section is now revised.
Action item: the following item is revised under the section "Abstract" on page 2 of the revised manuscript:
"The primary objective is the difference between the two groups in the proportion of patients who have reduced their inclusion dose of bDMARDs to 50% or less, while maintaining stable disease activity at 18 months follow-up." R2, Q5: The power for superiority in % <50% DDD is obviously very high, because this is an open door. In patients who are being tapered more will use a lower dose than patients who are not tapered.
R2, A5: We agree that the power for superiority of 0.992 appears extremely high; however, the sample size was determined from the power of the co-primary endpoint with the least statistical power i.e. primary endpoint 1B.
Action item: the following item is revised under the section "Sample size and power considerations" on page 12 of the revised manuscript:
"The sample size was determined from the power of the co-primary endpoint with the least statistical power i.e. primary endpoint 1B which is why the power for superiority of 0.992 appears extremely high." R2, Q6: You do not fully explain the 0.5 NI margin, but I think its fine.
R2, A6: Thank you for agreeing that the predefined margin of equivalence at ± 0.5 points is explained sufficiently even though it is not described in detail. Thus, as stated in the paper the margin was determined based on "less than half of the effect" that would be considered a clinically relevant reduction in DAS28crp level (∆DAS28crp > 1.2) or ASDAS level (∆ASDAS > 1.1) corresponding to a clinically unimportant change in arthritis disease activity.
R2, Q7: Being in remission is a suboptimal performing flare criterion, e.g. it is much too specific. When you include patients in deep remission, regression to the mean will result in many patient not being in deep remission anymore. See van der Maas 2013 OMERACT flare criteria paper. You analayse the mean in DAS28/ASDAS change, so this might not be an issue, but when talking about patients in remission it is.
R2, A7: Thank you for bringing to our attention that the primary objective was not described clearly in the paper. The primary objective are to evaluate whether a patient-centered tapering strategy for bDMARDs will enable a significant dosage reduction while maintaining disease activity assessed 18 months from baseline compared with usual care. Thus, we analyse the mean change in Das28crp/ASDAS and not if the patients maintain remission or not.
Action item: the following item is revised under the section "Primary outcome" on page 11 of the revised manuscript:
"The primary objective are to evaluate whether a patient-centered tapering strategy for bDMARDs will enable a significant dosage reduction while maintaining disease activity assessed 18 months from baseline compared with usual care. Thus, there are two primary efficacy endpoints: 1A Superiority: The proportion of patients who at 18 months are reduced to 50% or less of their inclusion dose of bDMARD. 1B Equivalence: Disease activity assessed 18 months from baseline. The primary objective is met if a statistically significant reduction in biologics is demonstrated while maintaining an equivalent disease state." R2, Q8: Patients: for RA patients this work has been done in the last year, see recent systematic reviews on the subject. Doing this for PsA and axSpA is important, because evidence is limited there. Consider focusing on those diseases. R2, A8: Thank you for this comment. We acknowledge, that randomised tapering studies have been performed in patients with RA during the last years; however, this RCT tapering trial include seven different bDMARDs, which to our knowledge has not been examined previously in RA, nor PsA or axSpA.
Action item: the following item is revised under the section "Discussion" on page 15 of the revised manuscript:
"The BIODOPT trial is to our knowledge the first randomised, equivalence trial exploring a disease activity guided tapering algorithm of 7 different bDMARDs including biosimilars among patients with inflammatory arthritis." R2, Q9: Remission as inclusion, especially this deep remission is troublesome. Firstly, those patients are rare, many patients are in LDA or normal remission, and treatment is not intensified. So a tapering study should included preferably all patient who have reached their treatment goal, and more often than not, it is not deep remission. Also, patients themselves identify the patient acceptable symptom state as being around DAS28 of between 3.0 and 3.5. Finally, a somewhat higher disease activity @ baseline is not a predictor (Effectmodifier) for successful tapering (tweehuijsen et al A &R 2017). So, there is no scientific or clinical reason not to include LDA patients, and it limits generalisability. R2, A9: Thank you for this comment. Previously, it have been discussed if disease activity at baseline could be an effect modification for successful tapering as results from different studies were conflicting. We chose sustained remission without swollen joints and with no steroid use within the last 12 months as an inclusion criteria to ensure that the included patients was in deep (true) remission before starting tapering of bDMARDs. However, as reviewer 2 points out, Tweehuysen et al. did not find evidence that disease activity at baseline is an effect modification for successful tapering. Consequently, we will strongly consider inclusion of patients in LDA with no swollen joints to improve the generalisability of the trial results.
Action item: the following item is revised under the section "Discussion" on page 16 of the revised manuscript:
"In existing studies, it have been discussed if disease activity at baseline could be an effect modification for successful tapering but the results were conflicting. (71) However, in a recent systematic review by Tweehuysen et al. it was concluded, that disease activity at baseline, i.e. remission or LDA, was not an effect modification for successful tapering of bDMARDs. (71) Consequently, we will strongly consider inclusion of patients in LDA with no swollen joints to improve the generalisability of the trial results." R2, Q10: Introduction: -please include a review on bDMARD dose reduction, for example the Cochrane, Verhoef et al 2017, or the ARD Fautrel paper 2017. You fr example do not mention the STRASS Fautrel study R2, A10: Thank you for making it clear that the introduction needed refinement. Two of the suggested reviews on bDMARD tapering is added to the reference list in the introduction and the introduction has been revised with inclusion of several trials including the STRASS trial.
Action item: the following item is inserted in the section "Introduction" on page 4 of the revised manuscript:
"Fautrel et al. did not disprove the null hypothesis of non-inferiority in the STRASS study due to insufficient recruitment; however, in the tapering group 18 months from baseline adalimumab or etanercept were successfully stopped in 39.1% and successfully tapered in 35.9% while standard dose had to be maintained in 20.3%. (31)" Action item: the following references is inserted in the section "Introduction" of the revised manuscript: R2, Q12: -line 58: This is a misconception I think. Many patient cannot stop directly, but this does not mean these patients could stop when they were slowly tapered. There are no data to suggest that, as successful stopping seems more rare even in tapering than in stopping trials. The benefit of tapering is to identify a third group, patient who can be tapered but not stopped. See also the Fautrel den Broeder paper 2015 best practices, R2, A12: Thank you for bringing to our attention that the sentence needed to be clarified. The sentence has been rewritten as described below.
Action item: the following item is revised under the section "Introduction" on page 3 of the revised manuscript:
"Thus, abrupt discontinuation of bDMARDs results in flare in a significant proportion of patients. Another approach is to use a tapering algorithm to gradually reduce dosage or increase the dosage interval of bDMARDs to identify patients who can taper or even discontinue their bDMARD." R2, Q13: -page 5 line 5: see my earlier comments. Patient guided tapering might motivate people better, but for sure it will lead to more expectation bias, nocebo and attribution. Please discuss these potential drawbacks. Of note, also in DRESS and STRASS tapering to the next step was Shared decision making between patients and physicians.
R2, A13: Thank you for the comment. The potential bias of the open-label design is now discussed in greater detail in the discussion section.
The following item is revised under the section "Discussion" on page 15 of the revised manuscript:
"However, a limitation is that the trial personnel and the patients are not blinded to the intervention groups; thus, this could potentially lead to bias e.g. nocebo, expectation and/or attribution bias which would affect interpretation of the trial results." R2, Q14: Methods: -you use a validated OMERACT Das28 flare criterion to assess flare and increase treatment, So, how is this different from the DRESS and STRASS studies? I don't see any more patient centeredness than in those studies R2, A14: Thank you for bringing to our attention, that the patient-centered algorithm needed clarification. In the BIODOPT trial, the patient is an equal partner in the shared decision during tapering of bDMARDs; thus, the patient can stop tapering prematurely and maintain the current dose or go one step back in the algorithm if he/she believe to have symptoms of activity even though the physician does not judge the arthritis to have flared. In contrast, the patients in the tapering group of the DRESS and STRASS studies were given a dose reduction advice.
"The BIODOPT tapering algorithm is patient-centered with focus on the patient's own perception of arthritis activity during tapering; thereby, making the patient an equal partner in their disease management as expected and required by modern society. Compared to a strict tapering algorithm focusing only on e.g. DAS28crp or joint swelling, the patient-centered BIODOPT algorithm is expected to enhance patient motivation during tapering; thereby, possibly increasing compliance. If the patient has symptoms of flare due to tapering but the arthritis is in remission assessed by the physician, the patient is generally advised to continue tapering according to the BIODOPT algorithm but may remain at the current dose (or even go back one step in the algorithm) after agreement between the patient and the physician." R2, Q15: -For PsA , DAS28 is a difficult to interpret measure. It misses out on skin, enthesis and axial complaints. Do you have any data on DAS28 based flare criteria in PsA?
R2, A15: Thank you for this comment. The (RA validated) DAS28 flare criteria was chosen for PsA as there currently are no flare criteria for PsA; however, we acknowledge that it would be desirably to monitor the patients with PsA using a PsA validated criteria (if this was possible). Previously, several tapering studies have used DAS28 ≥ 3.2 as a flare criteria in patients with PsA. I this trial, PsA essential outcomes as skin involvement, nail involvement, enthesitis and dactylitis will be monitored; hence, sub analysis will gather information about these outcomes in patients with PsA who taper their biologics. Furthermore, sub analysis will also involve information about reason for escalation dosage of bDMARDs e.g. skin psoriasis flare.
"However, we acknowledge that it would be desirably to monitor patients with PsA using a PsA validated flare criteria e.g. a DAPSA based flare criteria as DAPSA is used as remission criteria for enrolment in this trial. Nevertheless, DAPSA will be calculated for patients with PsA for each trial visit for further sub analysis. PsA and axSpA essential outcomes as skin involvement, nail involvement, enthesitis and dactylitis will be monitored; hence, sub analysis will be performed and information about reason for dosage escalation of bDMARDs will be collected e.g. skin psoriasis flare." R2, Q16: -Also, in PsA and axSpA -more so than in RA -extra-articular other associated disease might activate, like uveitis, psoriasis, IBD. Please add a strategy to cope with such an event.
R2, Q16: Thank you for bringing to our attention that this needed to be specified in the article. We have now described the study procedure regarding psoriasis, uveitis or IBD flare under the section "Flare criteria".
Action item: the following item is inserted under the section "Flare criteria" on page 7 of the revised manuscript:
"If a patient has symptoms of psoriasis, uveitis or IBD flare during tapering, the relevant department is contacted for dialogue and expert opinion in particular indication for bDMARD dosage escalation." R2, Q17: -Comparator strategy: in a pragmatic study, of course also in the UC group tapering can happen. However, with a NI or equivalence study, the main analyses are done per protocol, because in contrast to superiority studies, this is the more conservative approach. Do you have a per protocol analyses plan, because you state ITT as primary analysis? CONSORT now I think has reporting guidelines extension for NI and equivalence studies, please check these. R2, A17: Thank you for making it clear that the section "statistical analysis plan" needed to be refined. This protocol was developed in accordance with the EQUATOR recommendations (i.e. the CONSORT statements incl. the CONSORT statement for equivalence trials) which is now made clear in the paper. All analyses will be conducted according to the intention-to-treat (ITT) principle, which is one of the two recommended analyses for equivalence trials by CONSORT (the other is per protocol). From the CONSORT non-inferiority/equivalence statement:
"It should be indicated whether the conclusion relating to noninferiority or equivalence is based on ITT or perprotocol analysis or both and whether those conclusions are stable with respect to different types of analyses (eg, ITT, per-protocol)."
Action item: the following item is inserted under the section "Statistical analysis" on page 12-13 of the revised manuscript:
"All descriptive statistics and tests will be reported in accordance to the recommendations of the EQUATOR network (58) including the CONSORT statements. (59,60) Thus, all data analyses will be carried out according to a pre-established statistical analysis plan. Data will be analysed by the intention-to-treat principle, which is one of the recommended analyses for equivalence trials by CONSORT. (60) For the equivalence analyses (i.e. according to disease activity), imputations will not be used to replace missing data in the primary analyses, but will be included in a sensitivity analysis to assess the effect of missing data." R2, Q18: -You use three strata: in the analyses it is state of art to also correct for those strata, and preferably to show equivalence per stratum, at least drug and disease. Is this contemplated? R2, Q18: Thank you for the question. As stated in the paper, the primary analysis model will include group (i.e. intervention vs usual care), diagnosis, bDMARD failure history, centre status, and time point (4, 8, 12 months from baseline) as fixed effects, with the baseline value of the relevant variable (e.g. disease activity [1B]) as a covariate. Thus, the primary analysis will be stratified according to diagnosis group (RA, PsA or axSpA) but not to bDMARD drug. However, we will explore the effect of bDMARD drug in sub analyses.
Action item: the following item is inserted under the section "Statistical analysis" on page 14 of the revised manuscript:
"In addition, exploratory sub analysis will be performed to evaluate the effect of e.g. bDMARD drug." R2, Q19: -Multilevel analyses are fine, although you did not use a ML sample size calculation (I think for 2 levels they exist, not for n levels.) But the assumptions seem fine R2, A19: Thank you for raising this question. As stated in the DELTA 2 guideline for reporting sample size calculations in randomised controlled trials: under the conventional approach with a standard trial design and unadjusted statistical analysis, the core items that need to be stated are the primary outcome, the target difference appropriately specified according to the outcome type, the associated nuisance parameter, and the statistical significance and power. Even if the planned statistical analyses (e.g. hierarchical/multilevel analyses) deviates from the conventional approach (e.g. twosample t-tests), the core principles and reporting of sample size can be modified to provide sufficient detail to ensure that the sample size estimation is equally sophisticated. However, the key principles remain the same. Thus, the sample size calculation in this trial is done in accordance with the DELTA R3, Q1: • The primary outcome is the difference in percentage of patients that have at least a 50% dose reduction after 18 months of follow-up while staying in remission. The intervention is a combination of dose reduction and patient participation. It is not clear what % is expected to be due to patient education/participation and what due to the dose reduction. Since these are two interventions in one arm it should have been taken into account in the power calculation. Another way is to educate also the usual care patients.
Thank you for making it clear, that the patient education needed to be explained in greater detail in the protocol paper. It should now be clear that both groups are educated at baseline about symptoms of arthritis flare and to contact their outpatient clinic if such symptoms occur. This is why the patient education was not taken into consideration in the sample size calculation. This trial evaluates a patient-centered disease activity guided tapering algorithm compared with usual care practise. Previously, other models for dosage reduction of bDMARDs have been tested in patients with RA, PsA or axSpA; thus, this trial contributes with a new suggestion on how to taper patients with inflammatory arthritis.
Action item: the following item is inserted under the section "Interventions" on page 7 of the revised manuscript:
"At baseline, patients in both trial groups are educated about symptoms of flare by research personnel e.g. increasing peripheral joint pain and/or joint swelling and/or increasing inflammatory back pain. If such symptoms occur, the patients are advised to contact the rheumatology outpatient clinic for a consult within 7 days." R3, Q2: • The sample size was calculated based the expected results form previous studies in RA. In your study however, you include also PSA and axSPA, both indications that have shown to get flares after discontinuation bDMARDs. Therefor the expected % used in your power calculation is an overestimation that results in a smaller needed sample size than it should be. In my opinion this should be taken into account in the sample size calculation. Recalculated is advised.
R3, A2: Thank you for raising this concern as we have discussed the same aspect during the initial phase when designing the trial protocol. The sample size calculation for primary endpoint 1A was inspired from the RA-DRESS trial as it is one of the very few randomised, non-inferiority/equivalence trials exploring a disease activity guided tapering algorithm among patients with inflammatory arthritis. Based on the available literature (no randomised non-inferiority/equivalence study exploring a disease activity guided tapering algorithm is to our knowledge done in PsA or axSpA) it seems reasonable to assume that the percentage of patients with PsA or axSpA meeting primary endpoint 1A will be the same as for RA as described in the revised introduction. We acknowledge (as mentioned in the introduction of this paper), that abrupt discontinuation of bDMARDs in patients with PsA and axSpA leads to flare up in a larger proportion of patients compared to patients with RA. However, the literature exploring tapering in axSpA and PsA have not proven a very high flare rate as described in the revised introduction. Thus, the sample size calculation was not done for each disease group separately as it seems reasonable to assume that the proportion of patients who will meet primary endpoint 1A is equal among the three groups. In contrast to the DRESS study, the BIODOPT trial has two primary endpoints (1A and 1B) and both endpoints must be met i.e. proving a statistically significant reduction in biologics while maintaining an equivalent disease state.
"However, a non-inferiority trial including AS in remission on adalimumab, etanercept, infliximab or golimumab, which was stopped prematurely due to funding problems, found that prolonging the dosing interval of anti-TNF by 25% was non-inferior to full dosage anti-TNF as LDA was maintained in 81.3% of patients in the tapered group and 83.8% of patient in the full dose group. (22) (33, 34) In PsA, a prospective observation study has shown that 72% of patients treated with 25 mg etanercept maintained remission 1 year after a progressive dosage reduction with 21% receiving weekly dosage and 51% receiving a dosage every-other-week. (27) Additionally, in a case-control study including patients with PsA and RA in remission on adalimumab, the proportion of patients maintaining remission was statistically significant higher among patients with PsA (88.6%) than RA (17.6%) after 50% dosage reduction. (28)" Action item: the following item is inserted under the section "Sample size considerations" on page 11-12 of the revised manuscript:
"This assumption is inspired from the DRESS-RA trial, which it is one of the very few randomised, non-inferiority/equivalence trials exploring a disease activity guided tapering algorithm among patients with inflammatory arthritis. (30) No randomised non-inferiority/equivalence study exploring a disease activity guided tapering algorithm is done in PsA or axSpA, but based on the available literature it seems reasonable to assume that the percentage of patients with PsA or axSpA meeting primary endpoint 1A will be the same as for RA (26, 27, 29, 32) . Thus, the sample size calculation was not done for each disease separately." R3, Q3: • Another misinterpretation as you mentioned is using the DAS as flare outcome for PSA. However, especially these patients might stop dose reduction because of skin activity even when the joints are not inflamed. If there are more PSA patients than RA and/or AxSPA in your study population, this may underestimate your results. I suggest to include only RA patients R3, A3: Thank you for the comment. The (RA validated) DAS28 flare criteria was chosen for PsA as there currently are no flare criteria for PsA; however, we acknowledge that it would be desirably to monitor the patients with PsA using PsA validated criteria (if this was possible). I this trial, PsA essential outcomes as skin involvement, nail involvement, enthesitis and dactylitis will be monitored; hence, sub analyses will gather information about these outcomes in patients with PsA who taper their biologics. Furthermore, sub analysis will also contain information about reason for escalation dosage of bDMARD e.g. skin psoriasis flare. Currently, 69 patients diagnosed with RA, PsA or axSpA is included in the BIODOPT trial. The percentage of patients with PsA in the trial group is not greater than the percentage of patients with RA and/or axSpA; thus, we do not anticipate that using the DAS28 flare criteria for patients with PsA will result in an underestimation of the primary objective.
"However, we acknowledge that it would be desirably to monitor patients with PsA using a PsA validated flare criteria e.g. a DAPSA based flare criteria as DAPSA is used as remission criteria for enrolment in this trial. Nevertheless, DAPSA will be calculated for patients with PsA for each trial visit for further sub analysis." R3, Q4: • In your article you have to mention whether the patients are/are not allowed to taper conventional DMARDs. Especially since tapering cDAMRD also have effect on the primary outcome R3, Q4: Thank you for bringing this to our attention. A comment about concomitant synthetic DMARD have been added under the section "Interventions".
"Baseline concomitant synthetic DMARD and/or NSAID dose are maintained throughout the study period; however, dosage can be reduced or discontinued if the patient experience severe side effects." 
GENERAL COMMENT S
The authors have made a number of changes that improve the manuscript and the RCT itself. I have still 3 issues that should be resolved 1/ RA EULAR guideline specifically mentioned tapering as important and evidence based intervention, so to say that no guidelines mention tapering is incorrect. https://www.ncbi.nlm.nih.gov/pubmed/28264816 2/CONSORT is a reporting guideline, and does not advocate ITT or per protocol for NI or equivalence trials. However, in their suggested reporting, they mention per protocol, not intention to treat, as the primary analyses. http://www.consortstatement.org/Media/Default/Downloads/Extensions/CONSORT%20Extension%20fo r%20Non-inferiority%20and%20Equivalence%20Trials.pdf So, to state that CONSORT suggest ITT for NI/EQ studies is not correct 3/ The strong focus on patient centered tapering is strange: -All treat to target trials use a target, but also judgement on treatment changes both from the physician and the patient. There are no studies in which patients have to follow DAS28 score guided advices 100%. Protocol adherence in DRESS was approximately 75-80%, the same in the Best study (88%) and lower in IMPROVED study (65%). Patients can also drop out the study at any time, and stop tapering. When you mention protocolised tapering as having no patient involvement, I think this reflects limited experience with clinical strategy trials in rheumatology. All treatment decisions are "DAS28"inspired" but are made in shared decision making. I think Bruno Fautrel would tell you the same for the STRASS study ;). So patient centered tapering positioned against "protocolised" tapering, is "distinction without a difference". https://en.wikipedia.org/wiki/Distinction_without_a_difference -in your study, there is no process metnioned that leads to more patient involvement other than "physicians and patients decide together". There a some studies on implementation of Shared decision making, and SDM tools have been available. If you include these, I could appriciate more the distinction with usual T2T trials. -When tapering is done more according to patient preference, whatever that means, then I could see that more patients would be willing to taper. But that is not what you study. -
The statement that tapering would yield better results when patient are more involved in the decision making is very strange, because it suggest that often patients want to taper more, but are withheld by pohysicians or higher disease activity scores. This is to me unconceivable, and also not supported by evidence. You also rightfully state state that patient experienced flaring is characterized by more subjective complaints, so, more patient centered tapering would thus lead to less yield from tapering. There are no data to my knowledge that more patient involvement leads to less nocebo effects. Thus 1/ the focus on patient centered being different from other studies seems inappropriate and 2/ it will never lead to more tapering, but only to less tapering. I suggest to put less emphasis on the SDM part, and more on PsA/axSpA tapering and the several bDMARDS that are included.
REVIEWER
Tsutomu Takeuchi Keio University School of Medicine REVIEW RETURNED 12-Mar-2019
GENERAL COMMENTS
The authors extensively revised the manuscript according to the reviewers' suggestions. The reviewer have no further comments.
Moreover, the CONSORT statement for NI and EQ trials from 2010 mention both per protocol and ITT analysis but does not favour one over the other (page 2603):
Non-inferiority/Equivalence CONSORT (Piaggio, G et al) "It should be indicated whether the conclusion relating to noninferiority or equivalence is based on ITT or per protocol analysis or both and whether those conclusions are stable with respect to different types of analyses (eg, ITT, per-protocol)."
The primary (1A and 1B) and secondary endpoints in the BIODOPT trial will be conducted based on the intention-to-treat population; however, for these analyses we will not impute (i.e. "substitute") outcomes to replace missing data. According to the as observed principle, only patients with actual data collected in the database will be included in the analyses (independent of protocol violations).
Action item: the following item is inserted under the section "Statistical analysis" on page 12-13of the revised manuscript:
"The analyses for the primary and secondary endpoints will be conducted according to the ITT principle; i.e. based on the full analysis set (all randomised individuals independent of protocol violations) with outcome data available (as observed) (62). (62) For the equivalence analyses (i.e. according to disease activity), imputations will not be used to replace missing data in the primary analyses, but will be included in a sensitivity analysis to assess the effect of missing data. Thus, ITT analyses with replacement of missing data as well as analysis on "per protocol" individuals will only be performed to explore the robustness of our findings." R2, Q3: 3/ The strong focus on patient centered tapering is strange:
-All treat to target trials use a target, but also judgement on treatment changes both from the physician and the patient. There are no studies in which patients have to follow DAS28 score guided advices 100%. Protocol adherence in DRESS was approximately 75-80%, the same in the Best study (88%) and lower in IMPROVED study (65%). Patients can also drop out the study at any time, and stop tapering. When you mention protocolised tapering as having no patient involvement, I think this reflects limited experience with clinical strategy trials in rheumatology. All treatment decisions are "DAS28"inspired" but are made in shared decision making. I think Bruno Fautrel would tell you the same for the STRASS study ;). So patient centered tapering positioned against "protocolised" tapering, is "distinction without a difference". https://en.wikipedia.org/wiki/Distinction_without_a_difference -in your study, there is no process menioned that leads to more patient involvement other than "physicians and patients decide together". There a some studies on implementation of Shared decision making, and SDM tools have been available. If you include these, I could appriciate more the distinction with usual T2T trials.
-When tapering is done more according to patient preference, whatever that means, then I could see that more patients would be willing to taper. But that is not what you study.
-The statement that tapering would yield better results when patient are more involved in the decision making is very strange, because it suggest that often patients want to taper more, but are withheld by pohysicians or higher disease activity scores. This is to me unconceivable, and also not supported by evidence. You also rightfully state state that patient experienced flaring is characterized by more subjective complaints, so, more patient centered tapering would thus lead to less yield from tapering. There are no data to my knowledge that more patient involvement leads to less nocebo effects.
